2Limper AH,Knox KS,Sarosi GA,et al.An official American thoracic society statement:treatment of fungal infections in adult pulmonary and critical care patients[J].Am J Respir Crit Care Med,2011,183(1):96-128.
3Vargas K, Messer S A, Pfaler M A, et al. Elevated phenotypic switching and drug resistance of candida albicans from human immunodeficiency virus-positive in individuals prior to first thrush episode[J]. J Clin Microbiol, 2000, 28 (11):3595 -3607.
4Fichtenbaum C J, Powderly W G. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. [J]. Clin Infect Dis, 1998, 26 ( 3 ): 556 - 565.
5Moore C B, Sayers N, Mosquera J, et al. Antifungal drug resistance in aspergillus[J]. J Infect, 2000, 41 (2) :203 - 220.
6National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts;approved standard M27-A Villanova[S]. PA: NCCLS,1997.
7White T C, Marr K A, Bowden R A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance [J]. Clin MicrobiolRev, 1998, 11 (3) : 382-402.
8Marr K A, Lyons C N, Ha K, et al. Inducible azole resistance associated with a heterogeneous phenotype in candida albicans [J].Antimicrob Agents Chemother, 2001,45( 1 ): 52 -59.
9Perepnikhatka V, Fischer F J, Niimi M, et al. Specific chro-mosome alterations in fluconazole-resistance mutants of candida albicans [J].J Bacteriol, 1999, 181 ( 12 ): 4041 - 4049.
10Perfect J R, Cox G M. Drug resistance in cryptococcus neoformans[J]. Drugs, 1999, 2(2):259 -269.
